← All stories
Policy
Why Is AstraZeneca (LSE:AZN) Back in Focus After Fresh Regulatory News?
Highlights AstraZeneca has drawn fresh attention following a run of regulatory approvals and designations across its oncology portfolio The group's cardiovascular franchise also featured in recent updates, alongside continued investment in…
Covered by 1 outlet
All coverage · 1 article